Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in mice.

JCI insight·2026
Same author

Mannosylated nanoparticle immunogens enhance the circumsporozoite protein-specific B cell response and improve protection against sporozoite challenge.

bioRxiv : the preprint server for biology·2026
Same author

Multiplexed antigen panel analysis identifies B cell phenotype and receptor genetic contributions to antibody breadth.

Immunity·2026
Same author

Cross-coronavirus host susceptibility loci influence disease severity through immune mediators.

bioRxiv : the preprint server for biology·2026
Same author

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.

Nature microbiology·2026
Same author

Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.

Nature microbiology·2026

Related Experiment Video

Updated: Jun 18, 2025

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.4K

Computationally designed mRNA-launched protein nanoparticle vaccines.

Grace G Hendricks1,2, Lilit Grigoryan3, Mary Jane Navarro2

  • 1Institute for Protein Design, University of Washington, Seattle, WA, USA.

Biorxiv : the Preprint Server for Biology
|August 2, 2024
PubMed
Summary

New mRNA vaccines launch protein nanoparticles to combat SARS-CoV-2. This approach combines nanoparticle antigen display with mRNA

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
00:10

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.5K
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

11.1K

Related Experiment Videos

Last Updated: Jun 18, 2025

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.4K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
00:10

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.5K
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

11.1K

Area of Science:

  • Vaccinology
  • Immunology
  • Computational Biology

Background:

  • Protein nanoparticle and mRNA vaccines are established modalities with complementary strengths.
  • Protein nanoparticles enhance antibody responses, while mRNA vaccines offer rapid manufacturing and T cell immunity.
  • Computational protein design has advanced vaccine development.

Purpose of the Study:

  • To develop an mRNA-launched nanoparticle vaccine for SARS-CoV-2.
  • To leverage a computationally designed protein nanoparticle for enhanced vaccine delivery.
  • To combine the benefits of protein nanoparticle and mRNA vaccine platforms.

Main Methods:

  • Utilized a computationally designed icosahedral protein nanoparticle optimized for secretion.
  • Engineered the nanoparticle to display 60 copies of a stabilized SARS-CoV-2 Spike receptor binding domain (RBD).
  • Developed an mRNA vaccine encoding the secreted RBD nanoparticle and compared it to control vaccines in mice.

Main Results:

  • The secreted RBD nanoparticle formed stable, monodisperse assemblies.
  • The mRNA-launched nanoparticle vaccine induced 5- to 28-fold higher neutralizing antibodies than mRNA encoding membrane-anchored Spike.
  • The vaccine elicited superior CD8 T cell responses compared to adjuvanted protein nanoparticles and protected mice against SARS-CoV-2 challenge.

Conclusions:

  • Delivering protein nanoparticle immunogens via mRNA vaccines merges the advantages of both platforms.
  • Computational protein design is a powerful tool for genetic immunization strategies.
  • This approach shows promise for developing next-generation vaccines against SARS-CoV-2 and potentially other pathogens.